Incidence and Risk Factors for Hepatitis C Virus Infection among Illicit Drug Users in Italy
Authors:
- The Collaborative Study GroupTGThe Collaborative Study Group
- Enea SpadaESEnea Spada
- 4 December 2017
- journal article
- research article
- Published by Springer Nature in Journal of Urban Health
- Vol. 95 (1) , 99-110
Abstract
So far, only three small outdated studies have investigated hepatitis C virus (HCV) incidence and risk factors among illicit drug users (DUs) in Italy. Thus, during 2007–2010, we conducted a prospective cohort study among DUs attending 17 Italian rehabilitation centers serving urban areas. Two hundred eighty-four HCV-uninfected DUs were prospectively followed by interview and anti-HCV antibody and RNA testing every 6 months. Incidence was calculated using the person-years method. Infection predictors were assessed by time-dependent Cox analysis. Participants were mostly male (83.4%), under opioid substitution therapy (OST) (78.9%), non-injecting DUs (67.9%), and with a mean age of 30.8. Ninety-one of 224 DUs initially under OST interrupted treatment during the follow-up. Overall HCV incidence was 5.83/100 person-years at risk (PYAR) [95% confidence intervals (CI), 3.63–9.38]. The incidence did not significantly differ according the participants’ sociodemographic characteristics or the degree of urbanization of the towns involved in the study. The incidence was higher for DUs under than for those not under OST (6.23 vs 4.50/100 PYAR; p = 0.681). Incidence was also higher for those with than for those without OST interruption (7.17 vs 5.04/100 PYAR; p = 0.55). However, all these differences were non-significant. At last follow-up visit, a significant decrease in frequency of sharing equipment for preparation/using drugs (by injection or not) was observed by analyzing either the whole cohort or DUs under OST only. Anti-HCV seroconversion resulted independently associated with sharing drug preparation/use equipment, backloading, having a HCV-positive sexual partner, or household and (marginally) intravenous injection. In this study, HCV incidence was non-negligible and OST seemed to lack effectiveness in reducing it. In Italy, implementation of combined harm reduction interventions and antiviral treatment of chronically infected DUs would be needed.Keywords
Funding Information
- Isituto Superiore di Sanità-National Institute of Health Collaborative Programme (“Novel strategies toward developing a prophylactic and therapeutic vaccine against hepatitis C virus”; fasc. 30F3.
This publication has 41 references indexed in Scilit:
- Risk factors for and incidence of acute hepatitis C after the achievement of blood supply safety in Italy: Results from the national surveillance systemJournal of Medical Virology, 2012
- Hepatitis C prevalence in injecting drug users in Europe, 1990–2007: impact of study recruitment settingEpidemiology and Infection, 2012
- Meta‐analysis of hepatitis C seroconversion in relation to shared syringes and drug preparation equipmentAddiction, 2011
- Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviewsThe Lancet, 2011
- A Systematic Review and Meta-Analysis of Interventions to Prevent Hepatitis C Virus Infection in People Who Inject DrugsThe Journal of Infectious Diseases, 2011
- Hepatitis C virus risk behaviors within the partnerships of young injecting drug usersAddiction, 2010
- Intrafamilial transmission of hepatitis C virus in Italy: a systematic reviewJournal of Epidemiology and Community Health, 2009
- Full participation in harm reduction programmes is associated with decreased risk for human immunodeficiency virus and hepatitis C virus: evidence from the Amsterdam Cohort Studies among drug usersAddiction, 2007
- Non-injection drug use and Hepatitis C Virus: A systematic reviewDrug and Alcohol Dependence, 2007
- Major decline of hepatitis C virus incidence rate over two decades in a cohort of drug usersEuropean Journal of Epidemiology, 2007